What To Make of Roche's Drugs With $21 Billion In Sales Nearing Patent Expiry?


Roche Holding s 160 RHHBY 160 key blockbuster drugs Herceptin and Avastin will lose their market exclusivity in 2019 while another blockbuster drug Rituxan has already lost its exclusivity These three drugs are important for Roche as they generate 21 billion in annual